Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease

Charles L. Bennett1,2,3,4, Zaina P. Qureshi1,2,4, A. Oliver Sartor5, LeAnn B. Norris1,2, Alanna Murday1,2, Sudha Xirasagar5 and Henrik S. Thomsen6

1The Doris Levkoff Meddin Program on Medication Safety and the Southern Network on Adverse Reaction, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA, 2The Doris Levkoff Meddin Program on Medication Safety and the Southern Network on Adverse Reaction, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC, USA, 3The Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA, 4Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA, 5Department of Medicine: Section of Hematology & Medical Oncology and Department of Urology, Tulane School of Medicine and the Tulane Cancer Center, New Orleans, LA, USA, and 6Department of Diagnostic Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

Correspondence and offprint requests to: Charles L. Bennett; E-mail: charlesleebennett@gmail.com

Abstract

Background. In 2006, nephrologists in Denmark unexpectedly identified chronic kidney disease (CKD) patients with a new syndrome, nephrogenic systemic fibrosis (NSF). Subsequently, 1603 NSF patients were reported to the Food and Drug Administration. Sixty hospitals in the USA account for 93% of these cases, and two hospitals in Denmark account for 4% of these reports. We review Denmark's identification and subsequent rapid eradication of NSF.

Methods. NSF reports from clinicians, the Danish Medicines Agency (DMA) and gadolinium-based contrast agents (GBCAs) manufacturers were reviewed (2002–11).

Results. In 1994, the DMA approved a non-ionic linear GBCA, gadodiamide (0.1 mmol/kg), for magnetic resonance imagings (MRIs), with a renal insufficiency contraindication. In 1996, 0.3 mmol/kg dosing received DMA approval. In 1998, the DMA removed renal contraindications. In 1997 and 2002, radiologists at Skejby Hospital and Herlev Hospital, respectively, began performing gadodiamide-enhanced magnetic resonance angiography scans (0.3 mmol/kg) of CKD patients. In 2005, Herlev clinicians requested assistance in evaluating etiological causes of NSF occurring among 10 CKD patients who had developed NSF. This investigation, focusing on infectious agents, was inconclusive. In 2006, Herlev clinicians reported that of 108 CKD patients who had received gadodiamide-enhanced MRI, 20 had developed probable NSF. Herlev radiologists voluntarily discontinued administering gadodiamide to all patients and no new NSF cases at Herlev Hospital developed subsequently. After meeting with Herlev radiologists, Skejby radiologists also discontinued administering gadodiamide to all patients. In 2007, the European Medicines Agency and the DMA contraindicated gadodiamide administration to CKD patients. In 2008, in response to these advisories, radiologists at the other 36 Danish hospitals discontinued administering gadodiamide to all patients, following on practices adopted at Skejby and Herlev Hospitals. In 2009, clinicians at Skejby Hospital reported that a look-back survey identified 33 CKD patients with NSF developing after undergoing GBCA-enhanced MRIs between 1999 and 2007. In 2010, an independent review, commissioned by the Minister of Health, concluded that the DMA had erred in rescinding gadodiamide's renal insufficiency contraindication in 1998 and that this error was a key factor in the development of NSF in Denmark. In 2011, three NSF cases associated with macrocyclic GBCA-associated NSF and three NSF patients with Stages 3 and 4 CKD disease from Skejby Hospital were reported.

Conclusion. A confluence of factors led to the development and eradication of NSF in Denmark.

Keywords: chronic kidney disease; gadodiamide; gadolinium; magnetic resonance angiography; nephrogenic systemic fibrosis

Introduction

Nephrogenic systemic fibrosis (NSF) is a new and rare syndrome characterized by fibrotic skin, muscle contractions, decreased range of joint motion and organ fibrosis [1, 2]. Between 1997 and 2000, this syndrome was first diagnosed in 14 chronic kidney disease (CKD) patients who were receiving hemodialysis in California [2]. It can be painful, debilitating and even fatal [1]. In January 2006, an Austrian nephrologist reported that of nine CKD patients who had triple-dosed gadolinium-based contrast agent (GBCA)-enhanced magnetic resonance imaging (MRI) five developed NSF [3]. In March, a nephrologist at Denmark’s Herlev Hospital reported 20 CKD patients developing NSF following GBCA-enhanced MRIs...
In 1994, gadodiamide was approved by the DMA at a dose of 0.1 mmol/kg, with a contraindication initially for ‘reduced renal function’ [4, 5] and subsequently for ‘severe renal insufficiency’. The contraindication was based on the absence of safety data among patients with reduced renal function [4, 5]. In 1995, the DMA approved 0.3 mmol/kg dosing for evaluating brain metastases [4, 5]. In 1996, the DMA extended 0.3 mmol/kg dosing to general MRIs [4, 5]. In 1998, the renal insufficiency contraindication was revoked, based on a Herlev report identifying few side effects among 49 Norwegian and Danish CKD patients receiving gadodiamide (0.1 mmol/kg dosing)-enhanced MRI scans [4, 5, 8]. The manufacturer did not provide safety data for gadodiamide beyond 0.1 mmol/kg dosing.

Skejby Hospital actions (1997)

Skejby Hospital radiologists endorsed administration of GBCA to CKD patients, based on insights that the technique outperformed MRIs without contrast enhancement with respect to scan time and visualization performance [9]. Subsequently, 565 patients with reduced renal function had undergone GBCA-enhanced MRIs at Skejby Hospital.

Initial cases (2002–05)

In 2002, a nephrologist reported to the DMA and gadodiamide’s manufacturer a 44-year-old CKD male patient with severe muscle pain and oliguria beginning the day after undergoing a gadodiamide-enhanced magnetic resonance angiography (MRA) scan at Herlev. Shortly thereafter, two clinicians independently reported a 55-year-old CKD female patient experiencing severe skin, joint and muscle pain beginning immediately after undergoing a gadodiamide-enhanced MRA at Herlev. Both patients experienced oliguria following the procedure, requiring conversion from peritoneal dialysis to hemodialysis. Within weeks, the second patient was unable to walk due to extreme muscle and joint stiffness. In 2003, this patient died from a pulmonary embolism. The Patient Insurance Agency ruled that death resulted from gadodiamide toxicity and awarded a financial settlement. (Subsequently, biopsy materials confirmed NSF diagnosis [10].)

In 2003, a Herlev resident physician reviewed radiology and nephrology records for 104 CKD patients following gadodiamide-enhanced MRAs (0.3 mmol/kg) [11]. While two patients converted from peritoneal dialysis to hemodialysis (subsequently diagnosed as NSF), no other serious adverse events occurring within 2 weeks of gadodiamide administration were noted. This study concluded that gadodiamide-enhanced MRA was useful for evaluating arteries in patients with peripheral vascular disease [11]. Herlev nephrologists continued endorsing gadodiamide-enhanced MR examinations (0.3 mmol/kg), standard dosing for peripheral runoffs with available scanners.

In 2005, a Herlev resident physician, concerned that unknown exposures caused 10 CKD patients to develop NSF, requested assistance from the Board of Health epidemiologists [12]. Five patients had skin biopsies consistent with NSF. The investigation, focusing on infectious causes, was inconclusive.


In January, an Austrian report described five patients developing NSF shortly after undergoing GBCA-enhanced MRIs [3].

---

**Table 1. Gadolinium-containing agents and commercial names**

<table>
<thead>
<tr>
<th>Generic name</th>
<th>Brand name</th>
<th>Acronym</th>
<th>Chemical structure</th>
<th>Charge</th>
<th>Risk for NSF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gadodiamide</td>
<td>Omniscan</td>
<td>Gd-DTPA-BMA</td>
<td>Linear</td>
<td>Non-ionic</td>
<td>High</td>
</tr>
<tr>
<td>Gadodiamide</td>
<td>OptiMARK</td>
<td>Gd-DTPA-BMEA</td>
<td>Linear</td>
<td>Non-ionic</td>
<td>High</td>
</tr>
<tr>
<td>Gadopentetate dimeglumine</td>
<td>Magnevist</td>
<td>Gd-DTPA</td>
<td>Linear</td>
<td>Ionic</td>
<td>High</td>
</tr>
<tr>
<td>Gadobenate dimeglumine</td>
<td>MultiHance</td>
<td>Gd-BOPTA</td>
<td>Linear</td>
<td>Iodine</td>
<td>Medium</td>
</tr>
<tr>
<td>Gadacetic acid disodium salt</td>
<td>Eovist, Primovist</td>
<td>Gd-EOb-DTPA</td>
<td>Linear</td>
<td>Iodine</td>
<td>Medium</td>
</tr>
<tr>
<td>Gadofosveset triodium</td>
<td>Vasovist, Ablavar</td>
<td>Gd-DTPA</td>
<td>Linear</td>
<td>Iodine</td>
<td>Medium</td>
</tr>
<tr>
<td>Gadoteridol</td>
<td>ProHance</td>
<td>Gd-HP-D03A</td>
<td>Cyclic</td>
<td>Non-ionic</td>
<td>Low</td>
</tr>
<tr>
<td>Gadobutrol</td>
<td>Gadovist, Gadavist</td>
<td>Gd-BT-D03A</td>
<td>Cyclic</td>
<td>Non-ionic</td>
<td>Low</td>
</tr>
<tr>
<td>Gadoterate meglumine</td>
<td>Dotsarem</td>
<td>Gd-DOTA</td>
<td>Cyclic</td>
<td>Iodine</td>
<td>Low</td>
</tr>
</tbody>
</table>

*Not approved by the FDA

*Risk as noted by the EMA's Scientific Advice Group.

---

**Materials and methods**

Information was obtained from gadodiamide’s manufacturers, Denmark’s Patient Insurance Agency and the FDA (2002–10); Danish Medicines Agency (DMA) reports (2006 and 2008); Danish publications (2006–11); notifications from DMA, FDA and European Medicines Agency (EMA) (2006–10) and an independent report commissioned by Denmark’s Health Minister (2010) [3–34]. The case definition included clinically suspected or biopsy-confirmed NSF [1]. The project received Institutional Review Board approval from Northwestern University.

**Results**

**Regulatory history**

In 1994, gadodiamide was approved by the DMA at a dose of 0.1 mmol/kg, with a contraindication initially for ‘reduced renal function’ [4, 5] and subsequently for ‘severe renal insufficiency’. The contraindication was based on the absence of safety data among patients with reduced renal function [4, 5]. In 1995, the DMA approved 0.3 mmol/kg dosing for evaluating brain metastases [4, 5]. In 1996, the DMA extended 0.3 mmol/kg dosing to general MRIs [4, 5]. In 1998, the renal insufficiency contraindication was revoked, based on a Herlev report identifying few side effects among 49 Norwegian and Danish CKD patients receiving gadodiamide (0.1 mmol/kg dosing)-enhanced MRI scans [4, 5, 8]. The manufacturer did not provide safety data for gadodiamide beyond 0.1 mmol/kg dosing.
<table>
<thead>
<tr>
<th>Event</th>
<th>Action</th>
<th>Initial response</th>
<th>Later action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2002</strong></td>
<td>Index case develops acute skin toxicity immediately after undergoing a gadodiamide-enhanced MR at Herlev Hospital</td>
<td>Case reported to Danish Medicines Agency</td>
<td>Patient’s findings are categorized by the manufacturer as being consistent with underlying disease</td>
</tr>
<tr>
<td></td>
<td>Second NSF case undergoes skin biopsy</td>
<td>Pathologist reviews the biopsy</td>
<td>Pathologist reads the biopsy as being consistent with foreign body reaction</td>
</tr>
<tr>
<td></td>
<td>Second NSF case</td>
<td>Case reported to the manufacturer of gadodiamide by a dermatologist and a rheumatologist</td>
<td>Manufacturer classifies the case as exacerbation of underlying autoimmune disease</td>
</tr>
<tr>
<td><strong>2003</strong></td>
<td>Second Danish NSF case dies and Danish Patient Insurance Association awards large financial compensation</td>
<td>Danish Patient Insurance Association sends report of financial compensation to the manufacturer and states that patient’s death was probably a result of the gadodiamide administration</td>
<td>Manufacturer classifies the death as a consequence of underlying immunological disease</td>
</tr>
<tr>
<td></td>
<td>Manufacturer updates Periodic Safety Update Report (PSUR)</td>
<td>The PSUR does not list the first two NSF patients’ deaths as serious adverse drug reactions</td>
<td>The PSUR listing could have included the 2002 and 2003 cases as potential fatal adverse drug reactions</td>
</tr>
<tr>
<td><strong>2004</strong></td>
<td>Similar clinical findings for a CKD patient undergoing a gadodiamide-enhanced MR procedure in Texas</td>
<td>Radiologist in Texas telephones manufacturer to query whether any similar cases have been reported</td>
<td>Manufacturer does not link this case with the two index cases from Herlev Hospital in 2002</td>
</tr>
<tr>
<td></td>
<td>Manufacturer sends a PSUR to Danish regulatory authorities</td>
<td>All serious adverse drug reactions identified by the manufacturer are described</td>
<td>Details of the two Danish patients and the one Texas patient are not included in this 2004 PSUR prior to 2006</td>
</tr>
<tr>
<td><strong>2005</strong></td>
<td>A radiology resident published a Herlev Hospital retrospective study of 104 CKD patients who underwent gadodiamide-enhanced MR procedures in 2002 and 2003</td>
<td>Medical records and angiograms are reviewed by radiologists at Herlev Hospital</td>
<td>Records of only two patients identify skin and muscle changes following the MR procedure. The records were reviewed for evidence of nephrotoxicity and changes in vascular findings within days of the procedure.</td>
</tr>
<tr>
<td></td>
<td>A nephrology resident suspects that gadolinium might be the cause of acute skin changes and neuropathic symptoms of peritoneal dialysis patient exposed to gadodiamide in autumn 2005</td>
<td>Skin biopsy sent to a pathologist for examination for gadolinium in 2005</td>
<td>Methodology to identify gadolinium in skin biopsy is unavailable in 2005</td>
</tr>
<tr>
<td></td>
<td>Nephrologist suspects that common exposure might account for skin, muscle and joint changes in 10 CKD patients at Herlev Hospital</td>
<td>Medical record review is done. Summary table created in 2005 includes clinical findings and potential exposures</td>
<td>Gadolinium is listed as an exposure on only 2 of the 10 case summaries in the 2005 summary table</td>
</tr>
<tr>
<td></td>
<td>A fourth CKD patient develops acute toxicity following the gadodiamide-enhanced MR procedure</td>
<td>Clinicians in Germany report the details of this patient to the gadodiamide manufacturer of acute toxicity following the gadodiamide-enhanced MR procedure</td>
<td>Clinical details are not linked by safety personnel at the manufacturer with the prior three reports</td>
</tr>
<tr>
<td><strong>2006</strong></td>
<td>A Herlev Hospital nephrologist identifies 20 CKD patients with clinical diagnoses of NSF—all had undergone a gadodiamide-enhanced MR imaging procedure (early March 2006)</td>
<td>The Hospital nephrologist, Peter Markmann, telephones the Danish Medicines Agency and describes the 20 CKD patients as having clinical diagnoses of NSF—all had undergone a gadodiamide-enhanced MR imaging procedure (early March 2006). These reports form the basis for the Danish Medicines Agency dissemination of a statement of concern and are forwarded to the European Medicines Agency, FDA, and to gadodiamide’s manufacturer. (May 2006)</td>
<td>All 20 patients were later described in a written communication by the nephrologists to the DMA as clinically suspected NSF cases (Late March 2006). These reports form the basis for the Danish Medicines Agency dissemination of a statement of concern and are forwarded to the European Medicines Agency, FDA, and to gadodiamide’s manufacturer. (May 2006)</td>
</tr>
</tbody>
</table>
The specific GBCA was erroneously identified as gadopentetate dimeglumine. (This error was corrected in print in June 2006.)

In March, a Herlev Hospital nephrologist, Peter Marckmann, reported to the DMA that gadodiamide was a likely cause of NSF, based on his identification of 20 CKD patients developing NSF following gadodiamide-enhanced MRAs [4, 5, 10, 13]. Herlev radiologists voluntarily and immediately discontinued gadodiamide-enhanced MR investigations to all patients, substituting cyclic GBCAs [6, 12, 13].

In June 2006, NSF was discussed for the first time in the European Union's Side Effects Committee. At the time, the European Union had knowledge of the 20 Danish cases, 5 cases in Austria and an FDA database with 200 possible NSF cases from worldwide sources. The Committee acknowledged that there was no consensus on diagnostic criteria; documentation was incomplete in many cases particularly about which GBCA and what dose had been administered and whether a patient possibly could have received several different gadolinium-containing contrast agents. The Committee also considered the number of side effect reports to be very low compared to the information on the total use of gadodiamide and NSF reports were primarily from two European Union nephrology departments, despite wide use of gadodiamide internationally. Hence, there was skepticism with regard to a correlation between gadolinium and NSF.

In August, clinicians at Skejby Hospital reported that they had not diagnosed a single NSF case, despite routinely imaging CKD patients who were transplant candidates. Also, gadodiamide’s manufacturer advised 300 Danish radiologists and 114 Danish nephrologists in a letter that an NSF–gadodiamide association was observed among CKD patients at Herlev Hospital and that no causal relationship had been identified [12].

On 20 September, DMA met with gadodiamide’s manufacturer concerning NSF reports received from Herlev Hospital [4, 5, 12]. The DMA announced initiating an investigation and a causal relationship between gadodiamide and NSF was uncertain [4, 5, 12]. At the Danish council meeting on 27 September, a DMA representative said that it was problematic that Herlev Hospital radiologists had advised radiologists to avoid gadodiamide for CKD patients as a causal relationship had not been confirmed [12].

On 24 October, a conference on the NSF situation in western Denmark was held at the MRI center at Skejby Hospital. In attendance were Marckmann, representatives of the manufacturers of gadodiamide and gadopentetate dimeglumine and nephrologists from Skejby Hospital [4, 5, 12]. Nephrologists from Skejby Hospital reported that unique conditions at Herlev Hospital might have resulted in NSF cases at that hospital since cases were not recognized at other Danish hospitals. Nonetheless, for precautionary reasons and based on the Herlev Hospital information, Skejby Hospital discontinued administering gadodiamide [4, 5, 12, 14].

### 2007 European responses

In January, the Pharmacovigilance Working Party of EMA’s Committee for Medicinal Products for Humans (CMHP) recommended contraindicating gadodiamide among severe renal disease patients [5].

In February, the European Adverse Drug Reaction Council issued a strict contraindication against administering gadodiamide to severe renal disease patients and advised caution with other GBCAs [5]. The DMA issued new recommendations reflecting the Council’s decision.

In May, Herlev Hospital clinicians reported that among Stage 5 CKD patients, lifetime gadodiamide doses were 0.44 mmol/kg in 19 NSF cases versus 0.34 mmol/kg in 19 controls. Patients with severe versus less severe NSF received greater doses (0.57 versus 0.33 mmol/kg). NSF patients had a mean 14-day symptom-free period [15].

In June, the Council contraindicated administering another linear-chelated GBCA, gadopentetate dimeglumine, to severe CKD patients [5]. In July, the EMA’s CMHP approved gadoversetamidamide with the same renal contraindications [5].

In October, the European Society of Urogenital Radiology disseminated guidelines identifying three linear-chelated GBCAs as high NSF risk [16, 17].

In December, the Scientific Advisory Group for Diagnostics of EMA’s CMHP adopted this categorization [12].

### DMA reviews regulatory decisions (2008)

In February, the EMA endorsed its Scientific Advisory Group classification of GBCAs into three NSF risk groups and among high-risk GBCAs, NSF risks were highest with gadoversetamidamide and gadodiamide [4, 12]. In response to the EMA and DMA regulatory advisories contraindicating administration of linear-chelated GBCAs to CKD patients, Danish radiologists at 36 Danish hospitals adopted the practices that had been voluntarily implemented in 2006 at the two remaining Danish hospitals (Skejby and Herlev Hospitals) and discontinued administering non-ionic linear-chelated GBCAs to all patients, including CKD patients.

Also, in February, Denmark’s Secretary of Health commissioned DMA review gadodiamide’s regulatory handling [4, 12]. The report, submitted in March, concluded that the DMA had acted responsibly in approving gadodiamide in 1994 with a contraindication for severe renal insufficiency patients and in revoking this contraindication in 1998. The DMA indicated that upon reviewing Periodic Safety Update Reports, concerns regarding gadodiamide–NSF associations surfaced in 2006 [4, 12]. The DMA requested gadodiamide’s manufacturer comment on allegations that safety-related information had been withheld from...
Herlev radiologists. The manufacturer stated that in vitro and in vivo assessments did not support safety concerns and they had not ‘held back’ stability information [4, 12].

In March, Herlev Hospital clinicians reported higher NSF rates with gadodiamide versus other GBCAs (3–7 versus 0–1% per injection) [17] and severe NSF risk factors of higher cumulative gadodiamide doses, higher erythropoietin dosage and being on hemodialysis [18]. They reported an 18% NSF rate among 88 Stage 5 CKD patients versus 0% among 102 Stages 1–4 CKD patients [19].

In April, the Health Minister requested regional medical councils contact NSF patients [4, 12]. Also, gadodiamide’s manufacturer initiated a libel lawsuit in London against a Herlev Hospital radiologist who presented NSF findings at Oxford [20].

**Skejby NSF cases (2009)**

In January, clinicians from Skejby Hospital reported that in-person patient examinations and medical record reviews had identified 10 Stage 5 CKD patients with biopsy-confirmed NSF and 24 with clinically suspected NSF [12]. All had undergone GBCA-enhanced MRAs between 1999 and 2006 and most had received gadodiamide. (No NSF diagnoses had been listed in the patient’s medical records, hence the in-person examination was an important factor in identifying these patients.)

In February, Danish Parliament’s Health Committee summoned the Health Minister, requesting background about the 1998 DMA decision to rescind the contraindication against gadodiamide for severe renal insufficiency patients and about two NSF cases reported in 2002 to the DMA. The Minister commissioned an independent investigation of gadodiamide decisions by DMA, the Board of Health and the Health Ministry, which began in October 2009.

In September, Danish nephrologists described occasional NSF remission after recovery from acute renal failure or following kidney transplantation [22].

**The independent investigator’s report (2010)**

In February, the libel lawsuit filed by gadodiamide’s manufacturer against a Herlev radiologist was settled [12, 20].

In April, the DMA reported a national survey which identified 67 living NSF cases—36 following gadodiamide, 26 following gadodiamide and another GBCA and 5 following GBCAs other than gadodiamide. The national survey did not include patients undergoing radiography with GBCA. Also, the records of the patients were surveyed, while the skin in every patient was not inspected. The Patient Insurance Agency paid claims to 41 living disabled NSF patients (36 from gadodiamide, 4 from gadopentetate dimeglumine and 1 from gadofosveset trisodium). The EMA’s CMHP confirmed 67 living NSF cases—36 following gadodiamide, 26 following gadodiamide and another GBCA and 5 following GBCAs other than gadodiamide. The national survey did not include patients undergoing radiography with GBCA. Also, the records of the patients were surveyed, while the skin in every patient was not inspected. The Patient Insurance Agency paid claims to 41 living disabled NSF patients (36 from gadodiamide, 4 from gadopentetate dimeglumine and 1 from gadofosveset trisodium). The EMA’s CMHP indicated that among high-risk linear-chelated GBCAs, additional NSF risk factors included dose, frequency and duration of use [24].

**Autopsy findings (2011)**

In March, an autopsy report from Danish and US collaborators identified gadolinium phosphate deposits in cerebellum, skin, kidney, skeletal muscle and lymph nodes of NSF patients but not among patients unexposed to GBCAs and rarely among GBCA-associated CKD patients without clinical NSF signs [25].

In July, the manufacturer of gadodiamide provided DMA a copy of an internal draft report from 1994 identifying dissociation of gadodiamide in serum. (available at http://www.ugeskriftet.dk/portal/page/page/LAEGERDK/ UGESKRIFT_FOR_LAEGER?public_visningsType=5&public_modtager=0&public_forrigeVisningsType=4&public_nyhedsId=65909&public_afsender_gruppe=9,13).

In August, the journal *Academic Radiology* published a research letter from a Danish nephrologist and a radiologist who revisited a 1998 study which had concluded that gadodiamide could be administered safely to CKD Stage 5 patients [8, 35]. Safety assessments such as skin inspection after the follow-up were not done and only a single gadodiamide 0.1 mmol/kg dose was administered. With present knowledge, they report that the 1998 conclusion is not justified and gadodiamide is unsafe in CKD.

In October, a case–control study from clinicians at Skejby Hospital reported on 565 renal insufficiency patients with GBCA exposure between 1997 and 2009 [21]. They identified 17 NSF cases and 17 controls without signs of NSF. NSF prevalence was 4.7%, highest among CKD Stage 5 patients exposed to GBCA and undergoing hemodialysis or peritoneal dialysis. Three NSF cases were identified among patients with CKD Stages 3 and 4. Three patients developed possible NSF after macrocyclic GBCA exposure, although pathological findings for these patients do not fulfill current criteria for NSF [36]. NSF cases had a tendency to have higher serum phosphate concentrations than GBCA-exposed controls. They concluded that their updated findings indicated that CKD Stages 3 and 4 patients were at risk for NSF and that NSF may be triggered by macrocyclic GBCAs, although uncertainty over pathological confirmation of the NSF diagnoses limits the generalizability of their findings.

**Discussion**

At Skejby and Herlev Hospitals, the first gadodiamide-associated NSF cases occurred in 1998 and 2002, respectively, reached a maximum in 2005 and declined to one by 2008 [4, 12]. Throughout Denmark, no new NSF case has been reported since December 2008. (In the USA, home to 93% of reported NSF cases, the first case occurred in 1997, maximum reports of new cases were reached in 2006 and no new NSF cases were reported after 2009 [28, 30].) Patient, physician, hospital, product, regulatory and country considerations account for the emergence and disappearance of NSF in Denmark (Table 2).
As noted by the EMA in 2007 and FDA in 2010, GBCA-associated NSF rates were highest with linear-chelated GBCAs [24]. Scanning electron microscopy identified gadolinium in biopsies from NSF patients at Herlev [31]. Inductively coupled mass spectrometry confirmed the gadolinium [35]. Metal ions compete with gadolinium for ligand binding, a phenomenon called transmetallation. Impaired renal function and increased temperatures enhance transmetallation, by increasing linear-chelated GBCA’s half-life [8, 37]. Rodent and human studies demonstrate higher residual gadolinium levels with linear versus cyclic gadolinium chelates. Gadodiamide is associated with 93% of Danish and 70% of US NSF cases, while the linear GBCA gadopentate dimglutime is associated with 5% of Danish and 20% of US cases [4, 28, 30].

In Denmark in 1996, the DMA granted approval for gadodiamide at 0.3 mmol/kg dosing for general usage, while maintaining a contraindication against administration to CKD patients. In 1998, the DMA revoked this contraindication. Subsequently, Skejby Hospital and Rigshospital radiologists endorsed GBCA administration (dosages as high as 0.5 mmol/kg) for MRAs. Skejby and Rigshospital radiologists and vascular surgeons reported in 2001 that ‘there is no [GBCA] nephrotoxicity and maximum doses can be used safely in patients with renal insufficiency’ [9]. In 2001, Herlev purchased an MR scanner. In 2002, Herlev clinicians endorsed gadodiamide (0.3 mmol/kg) for CKD patients attempting to improve transplant recipient selection. While gadodiamide was administered at 38 hospitals in Denmark, most NSF reports were from Skejby and Herlev Hospitals, where gadodiamide 0.3 mmol/kg dosing to CKD patients was administered during NSF outbreak years [4, 5, 7, 10, 35]. Five Danish hospitals have renal transplantation programs (including Skejby and Herlev Hospitals), most CKD patients in Denmark are seen at these five hospitals and high doses of gadodiamide were administered predominantly at Skejby and Herlev Hospitals. Also, Danish NSF Investigation evaluated patients for NSF who were alive in 2009 and 2010. Several NSF patients may have died between 1998 and 2009 without being diagnosed with NSF and thus the actual number of NSF patients at the 38 Danish hospitals may have been greater than reported.

Our findings help explain the development and eradication of NSF cases in the USA and few cases in other countries. The manufacturer of gadodiamide reported to the FDA that NSF cases had been identified at 60 United States’ hospitals (all of which had large CKD and renal transplantation programs), although gadodiamide had been administered at 2100 United States’ hospitals [7, 27–30]. Gadodiamide-associated NSF in the USA is an example of toxicities associated with ‘indication creep’—drug use in ‘off-label’ indications [38]. After gadodiamide received FDA approval for 0.3 mmol/kg dosing for central nervous system MR imaging and for 0.1 mmol/kg dosing for MR body imaging in 1996, physicians endorsed 0.3 mmol/kg dosing ‘off-label’ for MRAs outside the central nervous system or during radiographic studies. Concurrently, multistationary MRAs requiring multiple bolus injections or one large bolus of GBCAs were being developed [39]. Gadodiamide safety would have been improved if practice had been guided by regulatory FDA approvals [40]. No NSF occurrences at most United States’ hospitals may be due to infrequent ‘off-label’ administration of linear-chelated GBCAs at 0.3 mmol/kg dosing to CKD patients. NSF occurs among patients with acute kidney injury, with CKD Stages 4 and 5 or among hemodialysis patients, particularly those with concomitant liver disease [1]. This observation provides rationale for evaluating renal function prior to administering high-risk GBCAs [41].

Our findings explain no new NSF cases being reported since 2007 in Denmark and 2009 in the USA. In Denmark, the peak number of NSF cases was in 2005, decreasing to zero by 2008, following decisions to substitute more stable GBCAs for gadodiamide among CKD patients. In the USA, FDA in September 2010 issued a requirement that patients be screened for CKD prior to undergoing GBCA-enhanced MR scans and issued a contraindication against administering linear-chelated GBCAs to CKD patients [27]. Peak United States NSF reports occurred in 2006. Following the FDA’s 2006 NSF notification of the Danish outbreak, GBCA administration to CKD patients decreased and, subsequently, NSF identification decreased precipitously. No new United States NSF cases were identified after 2009, when clinicians voluntarily discontinued administering linear-chelated GBCAs to CKD patients [28].

Our study has limitations. GBCA doses administered at hospitals other than Skejby and Herlev Hospital were not available for review. Additional NSF cases may have occurred and may not have been diagnosed or reported to regulatory agencies. The 2010 national survey in Denmark found 67 NSF cases, but the 2009 Skejby NSF notification included at least 15 deceased patients with signs and symptoms of NSF according to their medical records. An unknown number of deceased patients may have had NSF without any notations of clinical findings in their medical records. Therefore, the actual number of NSF patients in Denmark, a country of 5.5 million individuals, may be larger than the 82 patients reported to date to the DMA [12]. Finally, information included in the 2010 Attorney Report on NSF has not been available previously, and hence, a comprehensive analysis of NSF in Denmark was not possible previously. Despite these limitations, our review of the Danish NSF outbreak provides insights into the emergence of NSF as a clinical entity in Denmark in 1998 and its disappearance 10 years later. These insights also apply to the NSF experience in the USA during the years 1997 when NSF cases first developed through 2009 when the last NSF case in the USA occurred as well as to the observation that few NSF cases have been reported from countries other than Denmark and the USA. Clinicians should be cognizant of GBCAs’ risks and benefits. NSF fears should not lead to denial of enhanced MR imaging examinations with lower risk stable GBCAs, when clinically appropriate [34].

Acknowledgements. Author contributors: C.L.B. and H.S.T. conceived the idea, designed the study and collected the initial data. C.L.B., Z.P.Q., H.S.T., A.O.S. and L.N. contributed to the study design as well as analyzed and interpreted the findings. C.L.B., H.S.T., A.M., L.B.N., Z.P.Q., L.B.N. and S.X. contributed to the writing of the paper and approved the final draft. C.L.B. is the guarantor. Funded by grants from the National Cancer Institute [1R01CA102713-01 (Bennett)], from the Health Sciences South Carolina (Bennett) and from the South Carolina Center of Economic Excellence Center for Medication Safety Initiative. We would like to acknowledge the helpful comments of Peter Marckmann MD.

Conflict of interest statement. None declared.

References

8. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5: 491–502
19. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141–144
35. Joffe P, Thomsen HS. Gadodiamide in chronic kidney disease: it is not safe or harmless. Acad Radiol 2011; 18: 1060
38. Hebert PC, Stanbrook M. Indication creep: physician beware. CMAJ 2007; 177: 697, 9